Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC
Liquid biopsy has recently emerged as an important tool in clinical practice particularly for lung cancer patients. We retrospectively evaluated cell-free DNA analyses performed at our Institution by next generation sequencing methodology detecting the major classes of genetic alterations. Starting from the graphical representation of chromosomal alterations provided by the analysis software, we developed a support vector machine classifier to automatically classify chromosomal profiles as stable (SCP) or unstable (UCP). High concordance was found between our binary classification and tumor fraction evaluation performed using shallow whole genome sequencing. Among clinical features, UCP patients were more likely to have ≥ 3 metastatic sites and liver metastases. Longitudinal assessment of chromosomal profiles in 33 patients with lung cancer receiving immune checkpoint inhibitors (ICIs) showed that only patients that experienced early death or hyperprogressive disease retained or acquired an UCP within 3 weeks from the beginning of ICIs. UCP was not observed following ICIs among patients that experienced progressive disease or clinical benefit. In conclusion, our binary classification, applied to whole copy number alteration profiles, could be useful for clinical risk stratification during systemic treatment for non-small cell lung cancer patients.
Authors
- Elisabetta Zulato (ORCID: https://orcid.org/0000-0002-2624-5060)
- Stefano Indraccolo (ORCID: https://orcid.org/0000-0002-4810-7136)
- Valentina Guarneri (ORCID: https://orcid.org/0000-0002-2375-8397)
- Valeria Tosello (ORCID: https://orcid.org/0000-0001-9560-340X)
- Angela Grassi (ORCID: https://orcid.org/0000-0002-8313-8384)
- Maurizio Polano (ORCID: https://orcid.org/0000-0002-6101-1382)
- Chiara Dalle Fratte (ORCID: https://orcid.org/0000-0003-4205-2741)
- Paola Del Bianco (ORCID: https://orcid.org/0000-0002-6597-0265)
- Giulia Pasello (ORCID: https://orcid.org/0000-0002-8741-6038)
- Loc Carlo Bao
- Dominic Rose
- Laura Bonanno
Institutions
- University of Padua (IT)
- Roche Pharma AG (Germany) (DE)
- Istituto Oncologico Veneto (IT)
- Centro di Riferimento Oncologico (IT)
- CS Diagnostics (DE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1038/s41598-024-68229-6
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Ministero della Salute
- Istituto Oncologico Veneto